Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases

被引:2
作者
Boueiz, Adel [1 ]
Hassoun, Paul M. [1 ]
机构
[1] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA
关键词
Pulmonary arterial hypertension; connective tissue disease; systemic sclerosis; right ventricular failure; Saudi association for pulmonary hypertension guidelines; CONTINUOUS INTRAVENOUS EPOPROSTENOL; ANTIENDOTHELIAL CELL ANTIBODIES; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT-VENTRICULAR FUNCTION; CALCIUM-CHANNEL BLOCKERS; RIGHT HEART FUNCTION; SYSTEMIC-SCLEROSIS; SCLERODERMA SPECTRUM; RISK-FACTORS; DOPPLER-ECHOCARDIOGRAPHY;
D O I
10.4103/1817-1737.134016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States. ([1]) Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection.
引用
收藏
页码:26 / 37
页数:12
相关论文
共 142 条
[1]   Lessons learned from cancer may help in the treatment of pulmonary hypertension [J].
Adnot, S .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1461-1463
[2]   High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis [J].
Allanore, Y. ;
Avouac, J. ;
Zerkak, D. ;
Meune, C. ;
Hachulla, E. ;
Mouthon, L. ;
Guillevin, L. ;
Meyer, O. ;
Ekindjian, O. G. ;
Weber, S. ;
Kahan, A. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :284-291
[3]   A study of the prevalence of systemic sclerosis in northeast England [J].
Allcock, RJ ;
Forrest, I ;
Corris, PA ;
Crook, PR ;
Griffiths, ID .
RHEUMATOLOGY, 2004, 43 (05) :596-602
[4]   PREDICTORS OF SURVIVAL IN SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
ALTMAN, RD ;
MEDSGER, TA ;
BLOCH, DA ;
MICHEL, BA .
ARTHRITIS AND RHEUMATISM, 1991, 34 (04) :403-413
[5]  
Badesch DB, 2007, J RHEUMATOL, V34, P2417
[6]   Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry [J].
Badesch, David B. ;
Raskob, Gary E. ;
Elliott, C. Greg ;
Krichman, Abby M. ;
Farber, Harrison W. ;
Frost, Adaani E. ;
Barst, Robyn. J. ;
Benza, Raymond L. ;
Liou, Theodore G. ;
Turner, Michelle ;
Giles, Scott ;
Feldkircher, Kathy ;
Miller, Dave P. ;
McGoon, Michael D. .
CHEST, 2010, 137 (02) :376-387
[7]   Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol [J].
Badesch, David B. ;
McGoon, Michael D. ;
Barst, Robin J. ;
Tapson, Victor F. ;
Rubin, Lewis J. ;
Wigley, Fredrick M. ;
Kral, Kenneth M. ;
Raphiou, Ibrahim H. ;
Crater, Glenn D. .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) :2244-2249
[8]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[9]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[10]   Prevalence of pulmonary hypertension in limited and diffuse scleroderma [J].
Battle, RW ;
Davitt, MA ;
Cooper, SM ;
Buckley, LM ;
Leib, ES ;
Beglin, PA ;
Tischler, MD .
CHEST, 1996, 110 (06) :1515-1519